An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data

NCT02258854 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

69

Enrollment

INDUSTRY

Sponsor class

Conditions

Uveitis

Interventions

DRUG: Dose 2 gevokizumab

Sponsor

XOMA (US) LLC